| Weight | 1 kg |
|---|---|
| Dimensions | 10 × 10 × 10 cm |
| Pack Size | 100ul, 50ul |
| Immunogen Species | Human |
| Host | |
| Species Reactivity | Human |
| Tested Applications | ELISA, IHC, IF, FC, IP; Recommended dilution: IHC:1:50-1:200, IF:1:20-1:200, IP:1:200-1:1000 |
| Storage | -20?C or -80?C |
| BRAND | BIOTUVA, ELAB SCIENCE |
$315.00 – $525.00
Aliases
Prelamin-A/C, Lamin-A/C, 70 kDa lamin, Renal carcinoma antigen NY-REN-32, LMNA, LMN1
UniprotID
P02545
Immunogen
A synthesized peptide derived from human LMNA
SKU: BTV-RA013003A0HU
Categories: Antibody, Recombinant Antibodies
Be the first to review “LMNA Antibody” Cancel reply

IHC image of CSB-RA013003A0HU diluted at 1:115 and staining in paraffin-embedded human glioma cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4?C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
Related products
Antibody
$150.00 – $250.00
This product has multiple variants. The options may be chosen on the product page
Antibody
$150.00 – $250.00
This product has multiple variants. The options may be chosen on the product page
Antibody
$150.00 – $250.00
This product has multiple variants. The options may be chosen on the product page
Antibody
$150.00 – $250.00
This product has multiple variants. The options may be chosen on the product page
Antibody
$150.00 – $250.00
This product has multiple variants. The options may be chosen on the product page
Antibody
$150.00 – $250.00
This product has multiple variants. The options may be chosen on the product page
Antibody
$150.00 – $250.00
This product has multiple variants. The options may be chosen on the product page
Antibody
$150.00 – $250.00
This product has multiple variants. The options may be chosen on the product page




Reviews
There are no reviews yet.